Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JADE201 · 1 trial · 1 indication
Incidence of treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| JADE201 | EXPERIMENTAL | Subcutaneous (SC) injection of JADE201 |
| Placebo | EXPERIMENTAL | Subcutaneous (SC) injection of Placebo |
| Name | Type | Description |
|---|---|---|
| JADE201 | DRUG | JADE201 is supplied as sterile solution to be administered by SC injection. |
| Placebo | DRUG | Placebo solution to be administered at a matching volume by SC injection. |
Inclusion Criteria: 1. Male and female participants 18-70 years of age, inclusive. 2. A body weight between 50-100 kg and a body mass index (BMI) between 18-32 kg/m2 (all inclusive) at screening. 3. Confirmed diagnosis of RA according to 2010 ACR/EULAR criteria 4. Willing and able to comply with th...
JADE201 is an investigational small molecule being developed for the treatment of rheumatoid arthritis. It is currently in Phase 1 clinical development, with an ongoing study evaluating its safety and efficacy in participants with this condition.
JADE201 targets BAFF-R, a protein involved in the immune system. By targeting BAFF-R, JADE201 aims to modulate immune responses relevant to rheumatoid arthritis. This mechanism is being investigated in a Phase 1 clinical trial.
JADE201 is being developed by Jade Biosciences, Inc., a biopharmaceutical company. The company is conducting a Phase 1 clinical trial to evaluate the drug in participants with rheumatoid arthritis.
JADE201 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 1 study is currently recruiting participants with rheumatoid arthritis to assess its safety and tolerability.
JADE201 is being studied in a Phase 1 clinical trial with the identifier NCT07533955. This randomized, double-blind, controlled study is recruiting 36 participants with rheumatoid arthritis in Moldova and Ukraine. The trial is currently active and recruiting.
No alternative names for JADE201 have been disclosed. It is a distinct investigational small molecule developed by Jade Biosciences, Inc. for rheumatoid arthritis, and it is not known to be identical to any other approved or investigational drug.